PEOPLE - metaGen Gesellschaft fur Genomforschung (Germany) makes appointment:
This article was originally published in Clinica
Executive Summary
metaGen Gesellschaft fur Genomforschung (Berlin, Germany), a pharmaceutical R&D company using genomics and genetics-based technologies to develop new approaches to the diagnosis and treatment of cancer, has appointed Jurg Ambuhl as chief executive. He joins from BASF Pharma, where he was president of European and international operations.